Rupatadine – the facts speak for themselves Review article

Article Sidebar

Requires Subscription PDF (Język Polski)


Published: Dec 31, 2018
DOI: https://doi.org/10.24292/01.MF.0418.14
Keywords:
rupatadine, platelet-activating factor, allergic rhinitis, urticaria, treatment

Main Article Content

Adam J. Sybilski
1. Zakład Profilaktyki Zagrożeń Środowiskowych i Alergologii, Warszawski Uniwersytet Medyczny. 2. Klinika Chorób Dziecięcych i Noworodkowych, Centralny Szpital Kliniczny MSWiA w Warszawie

Abstract

Rupatadine is the first hybrid molecule, consisting of two connected but functionally separate pharmacological particles. It is a second-generation antihistamine with high H1 receptor blocking potency and a forceful receptor antagonist for platelet-activating factor (PAF). Rupatadine as an inhibitor of PAF inhibits mast cell degranulation, which is used in the treatment of allergic diseases. Rupatadine is rapidly absorbed from the gastrointestinal tract, and clinical studies have shown rapid onset of action and relief of symptoms as early as 12 hours after administration of the drug. Meta-analyzes confirmed the excellent efficacy of rupatadine in the treatment of allergic rhinitis and conjunctivitis and urticaria in adults and children. The drug has no effect of sedation, interaction with alcohol and with other drugs.

Article Details

How to Cite
Sybilski , A. J. (2018). Rupatadine – the facts speak for themselves. Medycyna Faktow (J EBM), 11(4(41), 339-342. https://doi.org/10.24292/01.MF.0418.14
Issue
Vol 11 No 4(41) (2018)
Section
Articles

Copyright © by Medical Education. All rights reserved.

References

1. Mullol J., Bousquet J., Bachert C. et al.: Rupatadine in allergic rhinitis and chronic urticaria. Allergy 2008; 63(Supl. 87): 5-28.
2. Merlos M., Giral M., Balsa D. et al.: Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF). J. Pharmacol. Exp. Ther. 1997; 280(1): 114-121.
3. Izquierdo I., Cranswick N., McCreanor J. et al.: Rupatadine in children aged 6-11 years with allergic rhinitis: a proof of concept evaluation by a 4 weeks treatment follow-up study. Pediatr. Allergy Immunol. 2009; 20(Supl. 20): 2.
4. Keam S.J., Plosker G.L.: Rupatadine: a review of its use in the management of allergic disorders. Drugs 2007; 67(3): 457-474.
5. Potter P., Maspero J., Vermeulen J. et al.: Rupatadine improves nasal symptoms control at 4 and 6 weeks in children with persistent allergic rhinitis. Allergy 2011; 66(Supl. 94): 11 (Abs. 23).
6. Łukaszyk M., Łukaszyk E., Wiśniewska R. et al.: Rupatadyna – lek przeciwhistaminowy o nowym mechanizmie działania. Alergia Astma Immunologia 2016; 21(4): 177-181.
7. Mullol J., Bousquet J., Bachert C. et al.: Update on rupatadine in the management of allergic disorders. Allergy 2015; 70: 1-24.
8. Munoz-Cano R., Valero A., Izquierdo I. et al.: Evaluation of nasal symptoms induced by platelet-activating factor, after nasal challenge in both healthy and allergic rhinitis subjects pretreated with rupatadine, levocetirizine or placebo in a cross-over design. Allergy Asthma Clin. Immunol. 2013; 9: 43.
9. Shamizadeh S., Brockow K., Ring J.: Rupatadine: efficacy and safety of a non-sedating antihistamine with PAF-antagonist effects. Allergo J. Int. 2014; 23: 87-95.
10. Sybilski A.J.: Pokrzywka i przewlekły alergiczny nieżyt nosa – nowe horyzonty leczenia u dzieci. Standardy Med. Pediatria 2014; 11: 685-692.
11. Compalati E., Canonica G.W.: Efficacy and safety of rupatadine for allergic rhino-conjunctivitis: a systematic review of randomized, double-blind, placebo-controlled studies with meta-analysis. Curr. Med. Res. Opin. 2013; 29: 1539-1551.